Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell dyscrasia and may represent a valid model for high-risk multiple myeloma (MM). To provide novel information concerning the mutational profile of this disease, we performed the whole-exome sequencing of a prospective series of 12 pPCL cases included in a Phase II multicenter clinical trial and previously characterized at clinical and molecular levels. We identified 1, 928 coding somatic non-silent variants on 1, 643 genes, with a mean of 166 variants per sample, and only few variants and genes recurrent in two or more samples. An excess of C > T transitions and the presence of two main mutational signatures (related to APOBEC over-activity and aging) occurring in different translocation groups were observed. We identified 14 candidate cancer driver genes, mainly involved in cell-matrix adhesion, cell cycle, genome stability, RNA metabolism and protein folding. Furthermore, integration of mutation data with copy number alteration profiles evidenced biallelically disrupted genes with potential tumor suppressor functions. Globally, cadherin/Wnt signaling, extracellular matrix and cell cycle checkpoint resulted the most affected functional pathways. Sequencing results were finally combined with gene expression data to better elucidate the biological relevance of mutated genes. This study represents the first whole-exome sequencing screen of pPCL and evidenced a remarkable genetic heterogeneity of mutational patterns. This may provide a contribution to the comprehension of the pathogenetic mechanisms associated with this aggressive form of PC dyscrasia and potentially with high-risk MM.

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns / I. Cifola, M. Lionetti, E. Pinatel, K. Todoerti, E. Mangano, A. Pietrelli, S. Fabris, L. Mosca, V. Simeon, M.T. Petrucci, F. Morabito, M. Offidani, F. Di Raimondo, A. Falcone, T. Caravita, C. Battaglia, G. De Bellis, A. Palumbo, P. Musto, A. Neri. - In: ONCOTARGET. - ISSN 1949-2553. - 6:19(2015), pp. 17543-17558. [10.18632/oncotarget.4028]

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns

I. Cifola
Primo
;
M. Lionetti
Secondo
;
K. Todoerti;E. Mangano;A. Pietrelli;S. Fabris;L. Mosca;C. Battaglia;A. Neri
2015

Abstract

Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell dyscrasia and may represent a valid model for high-risk multiple myeloma (MM). To provide novel information concerning the mutational profile of this disease, we performed the whole-exome sequencing of a prospective series of 12 pPCL cases included in a Phase II multicenter clinical trial and previously characterized at clinical and molecular levels. We identified 1, 928 coding somatic non-silent variants on 1, 643 genes, with a mean of 166 variants per sample, and only few variants and genes recurrent in two or more samples. An excess of C > T transitions and the presence of two main mutational signatures (related to APOBEC over-activity and aging) occurring in different translocation groups were observed. We identified 14 candidate cancer driver genes, mainly involved in cell-matrix adhesion, cell cycle, genome stability, RNA metabolism and protein folding. Furthermore, integration of mutation data with copy number alteration profiles evidenced biallelically disrupted genes with potential tumor suppressor functions. Globally, cadherin/Wnt signaling, extracellular matrix and cell cycle checkpoint resulted the most affected functional pathways. Sequencing results were finally combined with gene expression data to better elucidate the biological relevance of mutated genes. This study represents the first whole-exome sequencing screen of pPCL and evidenced a remarkable genetic heterogeneity of mutational patterns. This may provide a contribution to the comprehension of the pathogenetic mechanisms associated with this aggressive form of PC dyscrasia and potentially with high-risk MM.
whole-exome sequencing; plasma cell leukemia; multiple myeloma; mutations
Settore MED/15 - Malattie del Sangue
   The role of microRNA in multiple myeloma: biological and clinical implications
   FONDAZIONE AIRC PER LA RICERCA SUL CANCRO ETS
   IG 10136
2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
4028-60350-2-PB.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 4.15 MB
Formato Adobe PDF
4.15 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/281735
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 48
social impact